Sinil, Hanseo and Rexgene Biotech Undertake R&D Efforts on Novel Treatments

Published: 2005-01-05 06:59:00

Updated: 2005-01-05 06:59:00

Under the government initiatives to drive the development of novel pharmaceutical and biotechnology based treatments, three domestic companies Sinil Pharm, Hanseo Pharm, and Rexgene Biotech have recently made the project-based research and development agreements with the Ministry of Commerce, I...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK